Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1695875

	registered interest
	date	13/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Shingles: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of her Department's decision to exclude people aged between 66 and 69 on 1 September 2023 who do not have a severely weakened immune system in the phased roll-out of the shingles vaccination on those people.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	18597
	answer	answer is ministerial correction date of answer 20/03/2024 answer text <p>An assessment on the potential impact of not providing the vaccine to people aged 66 to 69 years old is not required, as they remain eligible to receive a shingles vaccination when they turn 70 years old, as they would have done prior to 1 September 2023.</p><p>The current policy offers the shingles vaccine Shingrix to anyone who turned 65 or 70 years old on or after 1 September 2023, and to anyone aged 50 years old and over who is at higher risk of serious complications as a result of having a severely weakened immune system.</p><p>This approach has been used in the effective implementation of previous immunisation programmes. Whilst some individuals may have to wait until they are eligible, the population benefit of adopting this approach is greater, meaning many individuals will receive the vaccine sooner and will benefit for longer.</p><p>The approach is modelled on the first shingles programme, optimizing achievements within the resources and capacity of the National Health Service, while being delivered alongside other important healthcare priorities, and avoiding undue additional pressure on NHS delivery services.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 20/03/2024 15:08:00 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4658 label Biography information for Alex Sobel

1695458

	registered interest
	date	12/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Construction
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has approved the business case costings for the New Hospital Programme.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	18276
	answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>On 25 May 2023, the Government announced that the New Hospital Programme (NHP) is expected to represent over £20 billion of capital investment for the financial year 2030/31, and that there would be a rolling programme of investment in health infrastructure in the longer term. Future spending beyond this current spending review period will be subject to the usual spending review processes.</p><p>The NHP has developed a third version of its Programme Business Case (PBC) which includes costs for the programme’s future spend. This was approved by the Department’s Joint Investment Committee on 19 February 2024. Following this approval, the PBC will go through Government assurance processes in May 2024.</p><p> </p><p>Future spend will be confirmed through the usual processes of future spending reviews, and all funding allocations for specific schemes within the NHP will only be confirmed once the individual Full Business Cases have been reviewed and agreed by ministers.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 15:18:09 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1689486

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how the £95 million allocated to the Dame Barbara Windsor Dementia Mission will be apportioned to (a) innovations in biomarkers, data, and digital and imaging technologies, (b) Increasing the number and speed of UK-based clinical trials for research into dementia and neurodegeneration and (c) its end-to-end implementation.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	14385
	answer	answer is ministerial correction date of answer 26/02/2024 answer text <p>The Dame Barbara Windsor Dementia Mission focuses on three key pillars. The first of which centres on biomarkers and experimental medicine, and will be allocated £44 million out of the total £95 million of funding for the mission, with the intention of securing match funding from industry partners. The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, and also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding. The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 26/02/2024 10:05:20 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1689525

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dulaglutide
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure the supply of Trulicity.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	14424
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>While the position has improved, there continues to be a global supply issue with glucagon-like peptide-1 receptor agonists (GLP-1 RA), including Trulicity (dulaglutide) and Ozempic (semaglutide). We have issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on the 3 January 2024, on how to manage patients requiring these medicines.</p><p>Our guidance is clear that GLP-1 RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose, and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and the Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.</p><p>We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help in ensuring that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14425 14426 question first answered 21/02/2024 16:10:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1689526

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dulaglutide
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support patients affected by shortages of Trulicity.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	14425
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>While the position has improved, there continues to be a global supply issue with glucagon-like peptide-1 receptor agonists (GLP-1 RA), including Trulicity (dulaglutide) and Ozempic (semaglutide). We have issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on the 3 January 2024, on how to manage patients requiring these medicines.</p><p>Our guidance is clear that GLP-1 RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose, and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and the Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.</p><p>We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help in ensuring that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14424 14426 question first answered 21/02/2024 16:10:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1689527

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help stop disruption of the supply of (a) Ozempic, (b) Trulicity and (c) similar medicines.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	14426
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>While the position has improved, there continues to be a global supply issue with glucagon-like peptide-1 receptor agonists (GLP-1 RA), including Trulicity (dulaglutide) and Ozempic (semaglutide). We have issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on the 3 January 2024, on how to manage patients requiring these medicines.</p><p>Our guidance is clear that GLP-1 RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose, and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and the Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.</p><p>We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help in ensuring that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14424 14425 question first answered 21/02/2024 16:10:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1689538

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tourette's Syndrome: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure that specialist medical services for Tourette's Syndrome are accessible to people outside of London.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	14437
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>Most services for people with Tourette’s syndrome are commissioned locally by integrated care boards (ICBs) as they are best placed to plan and improve the provision of services subject to local prioritisation and funding. I know, for example, that there have been recent ICB discussions within the provider trust in Leeds related to strengthening the local offer for Tourette’s syndrome.</p><p>Nationally, the government is taking steps to alleviate workforce demands to support services for Tourette’s syndrome. This includes, increasing the number of trained clinical psychologists available. Health Education England, now merged with NHS England, supported a 60 per cent expansion in the clinical psychology training intake over the past two years.</p><p>Clinical psychologist trainees are able to undertake specialist placements focusing on Tourette’s syndrome, in addition to Tourette’s syndrome featuring as part of the broader neuropsychology curriculum.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 27/02/2024 11:02:15 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4658 label Biography information for Alex Sobel

1676566

	registered interest
	date	08/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Oppositional Defiant Disorder
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of supporting all NHS Trusts to offer Oppositional Defiant Disorder as a diagnosis.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	5987
	answer	answer is ministerial correction date of answer 14/12/2023 answer text <p>There are no plans to make such an assessment. Individual diagnoses are a matter for clinicians. The National Institute for Health and Care Excellence provides national clinical guidelines concerning the recognition and management of conduct disorders in children and young people, including oppositional defiant disorder. We expect clinicians, commissioners, and providers to adhere to this guidance.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 14/12/2023 16:13:05 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4658 label Biography information for Alex Sobel

1675228

	registered interest
	date	04/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to tackle shortages in ADHD medications.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	5091
	answer	answer is ministerial correction date of answer 07/12/2023 answer text <p>We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to medicines for attention deficit hyperactivity disorder (ADHD) in the United Kingdom, in the short and long term.</p><p> </p><p>We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.</p><p> </p><p>Disruptions to the supply of medicines used for the management of ADHD have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, which should resolve by April 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/12/2023 13:01:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel

1675229

	registered interest
	date	04/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dentistry and Doctors: Ukraine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to enable (a) doctors and (b) dentists from Ukraine to practice in the UK.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	5092
	answer	answer is ministerial correction date of answer 07/12/2023 answer text <p>The General Medical Council (GMC) is the independent regulator of all medical doctors in the United Kingdom. The GMC has introduced several measures to support applications from Ukraine including waiving application fees and working with applicants to source documents. Information about these measures is available at the following link:</p><p><a href="https://www.gmc-uk.org/registration-and-licensing/join-the-register/before-you-apply/help-for-refugee-doctors" target="_blank">https://www.gmc-uk.org/registration-and-licensing/join-the-register/before-you-apply/help-for-refugee-doctors</a></p><p>The General Dental Council (GDC) is responsible for regulating dentistry qualifications and additions to the UK dental register. The GDC has advised that it is keen to support refugees with their registration applications wherever possible. Dedicated information for refugees is available at the following link:</p><p><a href="https://www.gdc-uk.org/registration/join-the-register/information-for-refugee-dental-professionals" target="_blank">https://www.gdc-uk.org/registration/join-the-register/information-for-refugee-dental-professionals</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/12/2023 12:15:15 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4658 label Biography information for Alex Sobel